Loading clinical trials...
Loading clinical trials...
A Six-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase II Study of the Efficacy and Safety of ACP-104 in Acutely Psychotic Subjects With Schizophrenia
Conditions
Interventions
ACP-104
ACP-104
+1 more
Locations
21
United States
Anaheim, California, United States
Costa Mesa, California, United States
Covina, California, United States
Culver City, California, United States
Garden Grove, California, United States
Glendale, California, United States
Start Date
June 1, 2007
Primary Completion Date
February 1, 2008
Completion Date
February 1, 2008
Last Updated
January 20, 2025
NCT06894212
NCT04226898
NCT05240976
NCT05304767
NCT06745479
NCT07455929
Lead Sponsor
ACADIA Pharmaceuticals Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions